OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Gastroenterology & Hepatology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
GORD: pain, PPIs, and preciseness	2025
Viral hepatitis: time for action	663
Nationwide practice change after early termination of a randomised trial of laparoscopic pancreatoduodenectomy	659
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply	475
Lucky: Learning to Live Again	475
EASL Congress 2024	455
Treatment withdrawal in Crohn's disease: slowly becoming clearer	409
Research in Brief	381
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship	306
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11	295
Thanks to our peer reviewers and contributors	280
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30	280
Appendicectomy: a disease-modifying treatment for ulcerative colitis?	279
Voices from the frontline: how global funding cuts are reshaping the viral hepatitis response	275
Developing policy for steatotic liver disease: an even better buy?	273
Correction to Lancet Gastroenterol Hepatol 2026; 11: 314–22	249
The central role of primary care in liver health	245
Cyclic exclusive enteral nutrition in paediatric Crohn's disease	231
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus	229
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium	225
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial	212
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial	204
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	201
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement	195
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	179

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial	175
Trends in alcohol-specific deaths in the UK and industry responses	173
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study	171
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	160
ACG 2024	156
Long-term VEDOKIDS results: implications for practice and research	153
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47	149
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply	144
Management of portal vein thrombosis in cirrhosis	141
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere	139
Water and sanitation for all	135
Idiopathic gastroparesis consensus misses the patient's voice	135
Research in Brief	132
Uptick of food allergies in recent years—real or epiphenomenon?	130
Has the time come for a systematic top-down approach in Crohn's disease?	129
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply	123
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis	122
Local and systemic therapy in liver cancer: the quest for synergy	122
The potential of ctDNA in locoregional therapies for colorectal cancer	114
All roads lead to the gut–brain microbiome network	108
Bringing organ preservation closer for selected patients with rectal cancer	104
Rare cause of dysphagia in a young woman	103
Availability of point-of-care HBV tests in resource-limited settings	101
Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy?	100
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised p	98
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial	97
Sex and gender in inflammatory bowel disease outcomes and research	96
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study	96
Resmetirom for NASH: balancing promise and prudence	95
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study	95
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review	93
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial	90
Lifting the minority tax in gastroenterology and hepatology	86
The Year My Life Went Down the Toilet	85
Management of malignant bowel obstruction – Authors' reply	85
A women-focused matrix mentorship programme in gastroenterology	84
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B	83
Another arrow in the NASH quiver?	82
Effects of lyophilised faecal filtrate compared with lyophilised donor stool on Clostridioides difficile recurrence: a multicentre, randomised, double-blinded, non-inferiority trial	82
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment de	81
Research in Brief	80
Practicalities accessing precision medicine in biliary tract cancer	80
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions	79
18th Congress of the European Crohn's and Colitis Organisation	79
An unusual complication after a variceal glue injection	79
Britta Siegmund: answering the big questions in IBD	78
The evolving clinical trial landscape in the MENA region	74
Redefining palliation in malignant gastric outlet obstruction	74
Managing inflammatory bowel disease: what to do when the best is unaffordable?	74
Shitbag: the story of a diagnosis	74

Robotic versus laparoscopic surgery for middle and low rectal cancer	74
Hypovolaemic phlebotomy for hepatic resection	73
The impact of 2025 US NIDDK funding cuts	72
CEND-1: a game changer for pancreatic cancer chemotherapy?	72
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations	71
Machine learning-based automated sponge cytology for screening of oesophageal squamous cell carcinoma and adenocarcinoma of the oesophagogastric junction: a nationwide, multicohort, prospective study	71
Urgent action needed to achieve viral hepatitis elimination	71
Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China	70
WHO global hepatitis report 2026: guiding global action for elimination	70
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial	70
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial	67
Primary biliary cholangitis and the narrowing gap towards optimal disease control	66
Research in brief	65
Scientific and medical evidence informing expansion of hepatitis B treatment guidelines	65
Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma	65
Primary intestinal lymphangiectasia	64
Bowel cancer prevention: are we missing an opportunity?	64
Management of portal vein thrombosis in cirrhosis – Authors' reply	64
Bringing dietary therapy for eosinophilic oesophagitis under scientific scrutiny	63
Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework	63
Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis	62
COP27 Climate Change Conference: urgent action needed for Africa and the world	62
The world is failing on hunger	61
The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership	61
Compensation advised for UK victims of contaminated blood scandal	61
Correction to Lancet Gastroenterol Hepatol 2023; 8: 908–18	61
Rethinking coeliac disease care: why psychological understanding matters	60
Clinical remission in ulcerative colitis: restoring precision in trial terminology	59
Alcohol and health: time for Europe to sober up	59
Increasing burden of colorectal cancer in China	58
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis	58
Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial	56
Correction to Lancet Gastroenterol Hepatol 2026; 11: 557–69	56
Lessons learned from the BOSS trial	56
Cirrhotic cardiomyopathy and portal hypertension: addressing the full disease spectrum in heart–liver co-management	56
Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines	55
Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study	55
The intestinal barrier: a pivotal role in health, inflammation, and cancer	54
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease	54
Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review	54
Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss (PRICE-2): a randomised controlled trial	53
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study	53
Diet or optimised medical therapy for people with irritable bowel syndrome	52
HIV pre-exposure prophylaxis as an entry point to the elimination of hepatitis B virus	52
PANTS extension study: how best to use anti-TNF drugs in Crohn's disease	52
Does filgotinib work for Crohn's disease?	52
Watch and wait for rectal cancer: towards data-informed surveillance	50
Correction to Lancet Gastroenterol Hepatol 2025; 10: 715–25	50
Early-onset colorectal cancer: Hollyoaks tackles taboos and raises awareness	50
DEI in gastroenterology and hepatology	49
Research in Brief	49
The British Association for the Study of the Liver commitment to equality, diversity, and inclusivity	48
Peroral endoscopic myotomy versus pneumatic dilation for achalasia	47
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection	47
Standardising early liver transplantation for severe alcohol-related hepatitis	45
Spleen stiffness in portal hypertension algorithms: the next advance	42
Lessons and open questions in borderline resectable pancreatic cancer	41
The role of [18F]FDG and [18F]FCH PET-CT in hepatocellular carcinoma with cirrhosis	41
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD	41
World Hepatitis Day 2025: elimination at a critical juncture	41
Addressing Africa's marginalisation in hepatocellular carcinoma clinical trials	40
Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysis	40
Gastroenterology training in Africa: an assessment of curriculum and perception	40
Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial	39
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised contro	39
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics	39
The liver–brain axis in metabolic dysfunction-associated steatotic liver disease	39
Elimination of hepatitis B requires recognition of catastrophic costs for patients and their families	38
Accelerating point-of-care HCV viral load testing	38
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-contr	38
Combination locoregional and systemic therapies in hepatocellular carcinoma	38
Pre-emptive TIPS for gastric variceal bleeding in patients with cirrhosis (GAVAPROSEC): an open-label randomised clinical trial	38
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	38
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study	37
A coordinated multipronged attack: integrated care is the future for gastroenterology	37
More is not always better for novel hepatitis B therapies	37
Time for a treat all approach for hepatitis B	37
The International Liver Congress 2022	36
Research in Brief	36
Research in Brief	36

Research in Brief	35
Oncological safety of laparoscopic surgery for low rectal cancer	35
Putting steatotic liver disease on the global NCD agenda	35
Correction to Lancet Gastroenterol Hepatol 2025; 10: 634–47	35
Inclusion of patients with isolated ulcerative proctitis in clinical trials	35
Launch of the International Living Donor Liver Transplantation Outcomes Registry	35
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from	35
An open letter to Gavi: hepatitis B birth dose vaccine can't wait	35
Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better	35
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomise	35
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis	34
Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial	34
All in her head: dismantling medical misogyny in disorders of gut–brain interaction	34
Metabolic syndrome myopathy: defining an emerging clinical entity in patients with MASLD	34
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions	33
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial	33
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy	32
The Liver Meeting 2023	32
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial	32
No accident: the UK infected blood scandal	32
Haematopoietic stem-cell transplantation in Crohn's disease	31
Chronic Boom	31
Hypovolaemic phlebotomy to reduce the need for perioperative transfusion: a price worth paying?	31
Tackling obesity: drugs are only part of the solution	31
Local ablation in pancreatic cancer: some answers and more questions	31
Retina and liver fibrosis screening for patients with type 2 diabetes	30
Research in Brief	30
Psychological therapies in inflammatory bowel disease	29
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes	29
The Liver Meeting 2025	29
Vedolizumab in paediatric IBD: a huge step forward but not there yet	28
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply	28
Challenging stigma around alcohol misuse	28
Terlipressin for hepatorenal syndrome: opportunities and challenges	28
Research in Brief	27
Séverine Vermeire: advancing patient-centred research in IBD	27
A new chapter in the campaign to eliminate viral hepatitis?	26
Cultural competence in the delivery of nutrition and symptom care in irritable bowel syndrome	26
Lessons from a trial of colesevelam for bile acid diarrhoea	25
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership	24
Robotic pancreatoduodenectomy: preparing for the future	24
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated rand	24
Correction to Lancet Gastroenterol Hepatol 2022; 7: 202–03	23
Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study	23
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study	23
Refining the faecal incontinence core outcome set – Authors' reply	23
A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia	23
The urgent need to end hepatitis B stigma and discrimination	23
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial	22
Diet or optimised medical therapy for people with irritable bowel syndrome	22
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based th	22
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial	22
Research in Brief	21
Variceal embolisation plus TIPS for variceal bleeding	21
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? – Author's reply	21
Financing viral hepatitis: catalysing action for impact	21
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary?	20
Liver disease admissions in the UK are increasing, urgently needing local and national solutions	20
No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis	20
Africa CDC's viral hepatitis prevention and control programme: a continental initiative to support elimination programmes	19
Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel	19
Africa must not be left out of the hepatitis B cure era	19
Non-coeliac gluten sensitivity: from Salerno to Rome	19
An important step towards the long-term treatment of eosinophilic oesophagitis	19
ASCO Gastrointestinal Cancers Symposium 2026	19
Expression of concern—Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre random	19
Difficulties in identifying a signal of activity in the adjuvant setting for biliary tract cancer	19
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial	18
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-b	18
Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions	18
Research in Brief	18
Antibiotic treatment versus appendicectomy for acute appendicitis in adults: an individual patient data meta-analysis	18
Single CT colonography versus three rounds of faecal immunochemical test for population-based screening of colorectal cancer (SAVE): a randomised controlled trial	18
Research in Brief	17
NAFLD prevalence and severity in overweight and obese populations	17
Intraoperative fluorescence angiography with indocyanine green to prevent anastomotic leak in rectal cancer surgery (IntAct): an unblinded randomised controlled trial	17
Weighing the benefits of screening for early-onset colorectal cancer	17
Global perspectives on sustainable IBD care	16
The first new drug for progressive familial intrahepatic cholestasis	16
Retina and liver fibrosis screening for patients with type 2 diabetes – Authors' reply	16
Proximal serrated polyp detection rate and interval post-colonoscopy colorectal cancer risk – Authors' reply	16
An Indigenous First Nations perspective on liver health	16
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial – Authors' reply	15
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial	15
Preventive cholera vaccination resumes	15
Targeting type 2 immune responses to treat eosinophilic gastritis	15
The promise of automated liver disease risk stratification in primary care	15
A path to global cirrhosis health equity	15
Effect of repeated elastography measurements in LiverScreen	14
Targeting the EGFR signalling pathway in metastatic colorectal cancer	14
Clinical outcomes of untreated adults living with chronic hepatitis B in The Gambia: an analysis of data from the prospective PROLIFICA cohort study	14
Uncouplers of mitochondrial oxidation in non-alcoholic fatty liver disease	14
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-infe	14
Pathogens don't respect politicians: US federal disruption poses a new threat to global public health	14
Pathophysiology of irritable bowel syndrome	14